[HTML][HTML] Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab
…, MD Rabena, M Maia, S Van Everen, K Le, WD Hanley - Retina, 2017 - journals.lww.com
Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and
ranibizumab in patients with neovascular age-related macular degeneration (AMD), …
ranibizumab in patients with neovascular age-related macular degeneration (AMD), …
[HTML][HTML] The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial
…, Y Chiang, JS Ehrlich, S Erickson, WD Hanley… - Ophthalmology, 2019 - Elsevier
Purpose To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS)
for neovascular age-related macular degeneration (nAMD) treatment. Design Phase 2, …
for neovascular age-related macular degeneration (nAMD) treatment. Design Phase 2, …
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir
LA Wenning, WD Hanley, DM Brainard… - Antimicrobial agents …, 2009 - Am Soc Microbiol
Raltegravir is a human immunodeficiency virus type 1 integrase strand transfer inhibitor that
is metabolized by glucuronidation via UGT1A1 and may be affected by inducers of UGT1A1, …
is metabolized by glucuronidation via UGT1A1 and may be affected by inducers of UGT1A1, …
CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity
WD Hanley, MM Burdick, K Konstantopoulos… - Cancer research, 2005 - AACR
Metastasis of circulating tumor cells requires a multistep cascade of events initiated by
adhesion of tumor cells to the vascular endothelium of involved tissues. This process occurs …
adhesion of tumor cells to the vascular endothelium of involved tissues. This process occurs …
Variant isoforms of CD44 are P‐and L‐selectin ligands on colon carcinoma cells
WD Hanley, SL Napier, MM Burdick… - The FASEB …, 2006 - Wiley Online Library
The initial selectin‐dependent events that mediate tumor cell tethering to platelets, leukocytes,
and vascular endothelium can regulate the extravasation and colonization of metastatic …
and vascular endothelium can regulate the extravasation and colonization of metastatic …
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with …
Purpose: Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer
and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized …
and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized …
[HTML][HTML] Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study)
…, T Csoszi, D Cernea, P O'Brien, WD Hanley… - Frontiers in …, 2016 - frontiersin.org
Background Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand
binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor …
binding to epidermal growth factor receptor (EGFR) and human epidermal growth factor …
Distinct kinetic and mechanical properties govern selectin-leukocyte interactions
WD Hanley, D Wirtz… - Journal of cell …, 2004 - journals.biologists.com
Leukocytes are recruited from the bloodstream to sites of inflammation by the selectin family
of adhesion receptors. In vivo and in vitro studies reveal distinctive rolling velocities of …
of adhesion receptors. In vivo and in vitro studies reveal distinctive rolling velocities of …
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type …
…, AV Kapp, RI Sufan, BB McCall, WD Hanley… - Clinical Cancer …, 2018 - AACR
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3.
Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type …
Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type …
Effects of omeprazole on plasma levels of raltegravir
…, AR Moreau, RR Rhodes, WD Hanley… - Clinical infectious …, 2009 - academic.oup.com
Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent
solubility. Raltegravir plasma concentration increases with omeprazole …
solubility. Raltegravir plasma concentration increases with omeprazole …